Legal
The company indicated then that it still believes all four HHS PrEP patents are invalid and should not have been granted.
Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.
Frank Reynolds, the founder and chief executive officer of PixarBio, was also ordered to repay $7.5 million to investors who backed the company’s non-opioid painkiller, NeuroRelease.
Did the price of a newly-approved treatment for a rare autoimmune disease and pressure from U.S. Sen. Bernie Sanders lead to the approval of a rival treatment? That’s what Florida-based Catalyst Pharmaceutical is attempting to show in court.
Bayer is moving closer to a $10 billion settlement over the Roundup lawsuits and the company is in the midst of restructuring.
Things are looking a little bit rosier for Elizabeth Holmes and the criminal charges against her after a federal judge dismissed some of the charges she is facing.
A four-year-old legal battle between Agilent Technologies and Twist Bioscience came to a conclusion Thursday. Twist agreed to pay Agilent $22.5 million to settle the lawsuit filed in 2016.
The Wuhan Institute of Virology, part of the China Academy of Sciences, has applied to patent the use of Gilead Sciences’ remdesivir to treat the current coronavirus outbreak.
Following a court’s ruling last week over a partial clinical hold placed on the company in 2018 by the U.S. Food and Drug Administration, Vanda Pharmaceuticals said it is undertaking a “comprehensive review” of the decision and will then determine the next appropriate steps.
The active component of the drug, sodium valproate, has been on the market for epilepsy and bipolar disorder since 1967.
PRESS RELEASES